Capital Advantage Inc. bought a new position in shares of Celgene Co. (NASDAQ:CELG) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,425 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Thompson Davis & CO. Inc. raised its stake in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI raised its stake in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Guidant Wealth Advisors purchased a new position in Celgene during the third quarter worth approximately $119,000. Motco raised its stake in Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in Celgene during the second quarter worth approximately $129,000. Institutional investors own 79.74% of the company’s stock.
Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the stock a “hold” rating in a research report on Friday. UBS Group lowered shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective for the company. in a research report on Thursday, October 26th. BMO Capital Markets dropped their price objective on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. BTIG Research reissued a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. Finally, Jefferies Group reissued a “buy” rating and issued a $160.00 price objective on shares of Celgene in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $132.63.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $1.58 EPS. equities research analysts forecast that Celgene Co. will post 6.68 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Capital Advantage Inc. Buys New Stake in Celgene Co. (CELG)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/12/30/capital-advantage-inc-buys-new-stake-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.